“The pharmaceutical industry has only begun to scratch the surface of employing digitally-based commercialization approaches. As POZEN moves forward to commercialize its PA pipeline, our goal in collaborating with these advisors is to look beyond the industry to identify untapped digital strategies that will help us deliver an affordable and accessible product to our customers,” said Liz Cermak, Executive Vice President and Chief Commercial Officer of POZEN. “POZEN feels privileged to be working with such accomplished and forward-looking individuals whose expertise and insights will help to shape our plans that will ultimately solidify our position as innovators.”
The POZEN Digital Advisory Board is comprised of leaders in technology, social media and digital marketing, bringing expertise and insights from a wide range of industries to POZEN. Any views or opinions expressed by the advisors as part of the Digital Advisory Board are their own and not those of their employers. The POZEN Digital Advisory Board includes:
- Raj Amin, Chief Executive Officer and Co-Founder, HealthiNation; previously Vice President of Business Development, N2 Broadband
- John Bax, Chief Financial Officer, LivingSocial; previously Chief Financial Officer, RecycleBank and Walmart.com
- Bonin Bough, Director of Digital and Social Media, PepsiCo; previously Director of Global Interactive, Social and Emerging Media Practice, Weber Shandwick
- Marc Monseau, Founder and Principal, MDM Communication, LLC; previously Director of Corporate Communication and Social Media, Johnson & Johnson
- Daniel Palestrant, M.D., Chief Executive Officer and Founder, Sermo; previously Founder, Azygos, Inc.
- Meredith Ressi, President, Manhattan Research; previously Chief Operating Officer, Integrated Wellness Solutions
The advisors will be participating in a media briefing and roundtable discussion on the topic of advancing the pharma model through lessons in digital later this year. Additional details will be forthcoming.
About POZEN
POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained U.S. Food and Drug Administration (FDA) approval of two self-invented products in two years – something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate PA32540 is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
About PA
POZEN is creating a portfolio of integrated aspirin therapies – the PA product platform. The products in the PA portfolio are intended to significantly reduce GI ulcers and other GI complications compared to taking aspirin alone.
The first candidate is PA32540. It is a coordinated-delivery tablet combining immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin. This novel, patented product is administered orally once a day and will be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers. POZEN has completed enrollment for the long-term safety study and continues enrollment on the two pivotal studies, targeting a New Drug Application filing in 2012.
Additionally, POZEN is conducting exploratory work on integrated aspirin therapies for other pain and pain-related conditions.
